Investigate / EW
Understand Edwards Lifesciences Corp
Can Edwards sustain adoption of its transcatheter valve therapies and broaden into new structural heart indications while managing its heavy dependence on one product group?
Snapshot reviewed 2026-10-02. Source published 2026-08-04. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / EW
Ask better questions. Keep the evidence.
Explore the available sources for Edwards Lifesciences Corp, then keep what deserves another look.
01 Investor activity
Who reports owning EW?
3 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Edwards develops structural heart devices, including surgical and transcatheter valve replacement and repair technologies, which clinicians use to treat heart valve disease in patients.
Latticework interpretation
What could support the case?
If clinical evidence keeps expanding the patients eligible for SAPIEN valves, adoption could broaden and support long-term use of the platform.
Latticework interpretation
What could break the case?
If Edwards fails to innovate on time, competitors' newer technologies could render its products obsolete or less competitive, and development or approvals might not be achieved.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Edwards develops structural heart devices, including surgical and transcatheter valve replacement and repair technologies, which clinicians use to treat heart valve disease in patients.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $1,741m | $1,532.2m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $513.2m | $411.2m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $241.9m | $333.2m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $695.7m | $570.6m |
Comparison caveat: Current net income reflects a deferred-tax valuation allowance following California legislation. Changes in tax expense matter alongside operating results; the net-income movement is not simply a change in product demand.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If clinical evidence keeps expanding the patients eligible for SAPIEN valves, adoption could broaden and support long-term use of the platform.
Supporting filing ↗The strongest caution
If Edwards fails to innovate on time, competitors' newer technologies could render its products obsolete or less competitive, and development or approvals might not be achieved.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How concentrated is the business in TAVR?
Starting evidence: TAVR is one of three product groups and the filing reports its share of net sales, so concentration may matter.
Investigate next: Review the full TAVR share of net sales over several years and the sales trends of TMTT and Surgical groups.
Read the supporting filing ↗Can growth extend beyond valve disease to heart failure?
Starting evidence: Edwards describes future growth as including treatment of non-valvular structural heart disease such as heart failure, whose success is uncertain.
Investigate next: Investigate the development stage, trial status and regulatory timelines of pipeline programs targeting heart failure.
Read the supporting filing ↗What effect might tariffs have on operations?
Starting evidence: Edwards says it may be unable to sufficiently mitigate tariff impacts, which could reduce demand and adversely affect results.
Investigate next: Examine disclosures on supply chain geography, tariff exposure and any mitigation measures in recent quarterly filings.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.